Bigelow Investment Advisors LLC Sells 2,516 Shares of Pfizer Inc. (NYSE:PFE)

Bigelow Investment Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 24,412 shares of the biopharmaceutical company’s stock after selling 2,516 shares during the quarter. Bigelow Investment Advisors LLC’s holdings in Pfizer were worth $703,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Moneta Group Investment Advisors LLC lifted its stake in shares of Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares during the period. Morgan Stanley lifted its stake in shares of Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares during the period. Norges Bank bought a new position in shares of Pfizer in the 4th quarter worth approximately $3,150,472,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in Pfizer by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after acquiring an additional 5,185,453 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 2.4 %

Shares of PFE stock traded up $0.61 on Friday, hitting $26.00. The stock had a trading volume of 37,897,818 shares, compared to its average volume of 42,423,477. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average price of $27.14 and a 200 day moving average price of $28.74. The company has a market cap of $147.23 billion, a PE ratio of 71.89, a P/E/G ratio of 1.15 and a beta of 0.61. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.